This systematic review and meta-analysis examined whether early tibial component migration, measured by radiostereometric analysis (RSA) at 1 year, predicts late aseptic revision in total knee arthroplasty. It pooled 50 RSA studies (847 implants) and 56 survival studies (20,599 implants) across 28 prosthesis-fixation-insert combinations. The goal was to establish evidence-based migration thresholds to guide phased introduction of new tibial implant designs.
Aseptic loosening of the tibial component is the leading cause of total knee arthroplasty failure — and it typically takes a decade to become symptomatic. RSA provides a way to identify high-risk implants within the first postoperative year, in studies of fewer than 60 patients.
The thresholds from this paper give concrete numbers to apply: MTPM below 0.54 mm at 1 year is acceptable, 1.6 mm or above is unacceptable, and anything between is a gray zone requiring watchfulness. These are not theoretical benchmarks — implants classified as unacceptable by these thresholds had already been withdrawn from clinical use in registries.
For a trainee, the clinical implication is twofold. First, early migration data from small RSA studies carries meaningful prognostic weight — a new implant without RSA data should prompt skepticism. Second, cementless implants without screw fixation carry a steeper revision penalty per millimeter of migration, which has direct relevance when choosing fixation construct for a given patient.
The phased introduction framework here — RSA screening first, then clinical outcomes, then registry surveillance — mirrors how regulators in the Netherlands and the NICE guidelines in the UK now approach new implant approval.
This systematic review and meta-analysis examined whether early tibial component migration, measured by radiostereometric analysis (RSA) at 1 year, predicts late aseptic revision in total knee arthroplasty. It pooled 50 RSA studies (847 implants) and 56 survival studies (20,599 implants) across 28 prosthesis-fixation-insert combinations. The goal was to establish evidence-based migration thresholds to guide phased introduction of new tibial implant designs.
Aseptic loosening of the tibial component is the leading cause of total knee arthroplasty failure — and it typically takes a decade to become symptomatic. RSA provides a way to identify high-risk implants within the first postoperative year, in studies of fewer than 60 patients.
The thresholds from this paper give concrete numbers to apply: MTPM below 0.54 mm at 1 year is acceptable, 1.6 mm or above is unacceptable, and anything between is a gray zone requiring watchfulness. These are not theoretical benchmarks — implants classified as unacceptable by these thresholds had already been withdrawn from clinical use in registries.
For a trainee, the clinical implication is twofold. First, early migration data from small RSA studies carries meaningful prognostic weight — a new implant without RSA data should prompt skepticism. Second, cementless implants without screw fixation carry a steeper revision penalty per millimeter of migration, which has direct relevance when choosing fixation construct for a given patient.
The phased introduction framework here — RSA screening first, then clinical outcomes, then registry surveillance — mirrors how regulators in the Netherlands and the NICE guidelines in the UK now approach new implant approval.